<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02973984</url>
  </required_header>
  <id_info>
    <org_study_id>28UCS2015</org_study_id>
    <secondary_id>162REG2016</secondary_id>
    <nct_id>NCT02973984</nct_id>
  </id_info>
  <brief_title>The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)</brief_title>
  <acronym>EUROSAF</acronym>
  <official_title>Evaluating the Efficacy and Risks of Anticoagulant Treatments in Multimorbid Frail Older Subjects With Atrial Fibrillation. The European Registry of Older Subjects With Atrial Fibrillation (EUROSAF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alberto Pilotto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Ospedali Galliera</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Preliminary data suggest that:

        1. a different risk of mortality, as assessed by the Multidimensional Prognostic Indices
           (MPI), may influence the anticoagulant prescription in older subjects with Atrial
           Fibrillation (AF);

        2. the presence of multidimensional impairment, disability and multi-morbidities are
           usually not included in the decision algorithm of the more appropriate treatments in
           older patients with AF;

        3. considering the prognostic information, as calculated by the MPI, can be useful to
           physicians in identifying older patients with AF that can benefit from anticoagulant
           treatment in term of increased survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this observational study is to evaluate in a &quot;real world&quot; population of
      older hospitalized patients with AF, the clinical benefit/risk ratio of the anticoagulant
      treatments in terms of:

        1. mortality (all-cause and vascular mortality);

        2. thromboembolic events, i.e. stroke, systemic embolism;

        3. bleeding side-effects, especially intracranial and gastrointestinal bleeding Secondary
           objective of the study is to evaluate whether a different prognostic profile, as
           determined by the MPI, is associated with 1) different kind of treatments for AF (no
           treatment vs anticoagulants, i.e. Vitamin K Antagonists (VKA) or novel oral
           anticoagulant (NOACs); and 2) differences in the main outcomes (i.e. mortality, major
           thromboembolic events and side effects including bleeding events).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 18, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>all-cause mortality and vascular mortality</measure>
    <time_frame>12 months</time_frame>
    <description>Vascular mortality is defined as: stroke, embolism, myocardial infarction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>thromboembolic events,</measure>
    <time_frame>12 months</time_frame>
    <description>stroke and/or systemic embolism</description>
  </primary_outcome>
  <primary_outcome>
    <measure>bleeding side-effects</measure>
    <time_frame>12 months</time_frame>
    <description>major intracranial and gastrointestinal bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>vascular-related hospitalization rates</measure>
    <time_frame>12 months</time_frame>
    <description>stroke and/or systemic embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>bleeding-related hospitalization rates</measure>
    <time_frame>12 months</time_frame>
    <description>intracranial and gastrointestinal bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPI value and different mortality risk class</measure>
    <time_frame>12 months</time_frame>
    <description>mild, moderate, severe</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>presence/absence of anticoagulant treatments</measure>
    <time_frame>12 months</time_frame>
    <description>presence of anticoagulant treatments</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This is a cross-national, prospective, observational study that will include about 3.000
        older subjects (aged ≥ 65 years) with AF hospitalized in 30 European geriatric centers
        (about 100 subjects/center) for an acute disease or a relapse of a chronic diseases. The
        study is in the frame of the Special Interest Group on CGA (Comprehensive Geriatric
        Assessment) of the EUGMS (European Union Geriatric Medicine Society).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        This is an observational study in which all consecutive patients admitted to the Geriatrics
        Units involved in the project will be screened for inclusion. The inclusion criteria are:

          1. patients of both genders, aged 65 years and older

          2. admitted to hospital for acute diseases or a relapse of chronic diseases

          3. with a documented diagnosis of non valvular AF

          4. who are willing to participate in the survey and give their informed consent

        Exclusion Criteria:

          1. age less than 65 years

          2. patients who have not provided informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Pilotto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento: area delle cure geriatriche, ortogeriatria e riabilitazione - E.O. Ospedali Galliera - Genova Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alberto Pilotto, MD</last_name>
    <phone>0039 010 563</phone>
    <phone_ext>4467</phone_ext>
    <email>alberto.pilotto@galliera.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alessandra Argusti, PDH</last_name>
    <phone>0039 010 563</phone>
    <phone_ext>4188</phone_ext>
    <email>a.argusti@galliera.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>S.C. Geriatria</name>
      <address>
        <city>Genova</city>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Pilotto, MD</last_name>
      <phone>0039 010 536</phone>
      <phone_ext>4467</phone_ext>
      <email>alberto.pilotto@galliera.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisabetta Canepa, PhD</last_name>
      <phone>0039 010 563</phone>
      <phone_ext>4439</phone_ext>
      <email>elisabetta.canepa@galliera.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.mpiage.eu/home/about-mpi</url>
    <description>software for Windows to calculate the MPI.</description>
  </link>
  <reference>
    <citation>Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Le Heuzey JY, Kay GN, Olsson SB, Prystowsky EN, Tamargo JL, Wann S. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013 May 7;61(18):1935-44. doi: 10.1016/j.jacc.2013.02.001. Epub 2013 Apr 1. Review.</citation>
    <PMID>23558044</PMID>
  </reference>
  <reference>
    <citation>Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH; ESC Committee for Practice Guidelines. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010 Oct;12(10):1360-420. doi: 10.1093/europace/euq350. Erratum in: Europace. 2011 Jul;13(7):1058. Dosage error in article text.</citation>
    <PMID>20876603</PMID>
  </reference>
  <reference>
    <citation>Hylek EM, D'Antonio J, Evans-Molina C, Shea C, Henault LE, Regan S. Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation. Stroke. 2006 Apr;37(4):1075-80. Epub 2006 Mar 9.</citation>
    <PMID>16527999</PMID>
  </reference>
  <reference>
    <citation>Pugh D, Pugh J, Mead GE. Attitudes of physicians regarding anticoagulation for atrial fibrillation: a systematic review. Age Ageing. 2011 Nov;40(6):675-83. doi: 10.1093/ageing/afr097. Epub 2011 Aug 5. Review.</citation>
    <PMID>21821732</PMID>
  </reference>
  <reference>
    <citation>Maes F, Dalleur O, Henrard S, Wouters D, Scavée C, Spinewine A, Boland B. Risk scores and geriatric profile: can they really help us in anticoagulation decision making among older patients suffering from atrial fibrillation? Clin Interv Aging. 2014 Jul 15;9:1091-9. doi: 10.2147/CIA.S62597. eCollection 2014.</citation>
    <PMID>25053883</PMID>
  </reference>
  <reference>
    <citation>Sinnaeve PR, Brueckmann M, Clemens A, Oldgren J, Eikelboom J, Healey JS. Stroke prevention in elderly patients with atrial fibrillation: challenges for anticoagulation. J Intern Med. 2012 Jan;271(1):15-24. doi: 10.1111/j.1365-2796.2011.02464.x. Epub 2011 Oct 31. Review.</citation>
    <PMID>21995885</PMID>
  </reference>
  <reference>
    <citation>Zarraga IG, Kron J. Oral anticoagulation in elderly adults with atrial fibrillation: integrating new options with old concepts. J Am Geriatr Soc. 2013 Jan;61(1):143-50. doi: 10.1111/jgs.12042. Epub 2012 Dec 18. Review.</citation>
    <PMID>23252345</PMID>
  </reference>
  <reference>
    <citation>Barco S, Cheung YW, Eikelboom JW, Coppens M. New oral anticoagulants in elderly patients. Best Pract Res Clin Haematol. 2013 Jun;26(2):215-24. doi: 10.1016/j.beha.2013.07.011. Epub 2013 Jul 21. Review.</citation>
    <PMID>23953909</PMID>
  </reference>
  <reference>
    <citation>Sardar P, Chatterjee S, Chaudhari S, Lip GY. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc. 2014 May;62(5):857-64. doi: 10.1111/jgs.12799. Epub 2014 May 1. Review.</citation>
    <PMID>24786913</PMID>
  </reference>
  <reference>
    <citation>Stöllberger C, Finsterer J. Concerns about the use of new oral anticoagulants for stroke prevention in elderly patients with atrial fibrillation. Drugs Aging. 2013 Dec;30(12):949-58. doi: 10.1007/s40266-013-0119-3. Review.</citation>
    <PMID>24170233</PMID>
  </reference>
  <reference>
    <citation>Crome P, Lally F, Cherubini A, Oristrell J, Beswick AD, Clarfield AM, Hertogh C, Lesauskaite V, Prada GI, Szczerbińska K, Topinkova E, Sinclair-Cohen J, Edbrooke D, Mills G. Exclusion of older people from clinical trials: professional views from nine European countries participating in the PREDICT study. Drugs Aging. 2011 Aug 1;28(8):667-77. doi: 10.2165/11591990-000000000-00000.</citation>
    <PMID>21812501</PMID>
  </reference>
  <reference>
    <citation>Gill TM. The central role of prognosis in clinical decision making. JAMA. 2012 Jan 11;307(2):199-200. doi: 10.1001/jama.2011.1992.</citation>
    <PMID>22235093</PMID>
  </reference>
  <reference>
    <citation>Pilotto A, Ferrucci L, Franceschi M, D'Ambrosio LP, Scarcelli C, Cascavilla L, Paris F, Placentino G, Seripa D, Dallapiccola B, Leandro G. Development and validation of a multidimensional prognostic index for one-year mortality from comprehensive geriatric assessment in hospitalized older patients. Rejuvenation Res. 2008 Feb;11(1):151-61. doi: 10.1089/rej.2007.0569.</citation>
    <PMID>18173367</PMID>
  </reference>
  <reference>
    <citation>Pilotto A, Gallina P, Fontana A, Sancarlo D, Bazzano S, Copetti M, Maggi S, Paroni G, Marcato F, Pellegrini F, Donato D, Ferrucci L. Development and validation of a Multidimensional Prognostic Index for mortality based on a standardized Multidimensional Assessment Schedule (MPI-SVaMA) in community-dwelling older subjects. J Am Med Dir Assoc. 2013 Apr;14(4):287-92. doi: 10.1016/j.jamda.2013.01.005. Epub 2013 Feb 9.</citation>
    <PMID>23402948</PMID>
  </reference>
  <reference>
    <citation>Siontis GC, Tzoulaki I, Ioannidis JP. Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med. 2011 Oct 24;171(19):1721-6. doi: 10.1001/archinternmed.2011.334. Epub 2011 Jul 25.</citation>
    <PMID>21788535</PMID>
  </reference>
  <reference>
    <citation>Yourman LC, Lee SJ, Schonberg MA, Widera EW, Smith AK. Prognostic indices for older adults: a systematic review. JAMA. 2012 Jan 11;307(2):182-92. doi: 10.1001/jama.2011.1966. Review.</citation>
    <PMID>22235089</PMID>
  </reference>
  <reference>
    <citation>Pilotto A, Rengo F, Marchionni N, Sancarlo D, Fontana A, Panza F, Ferrucci L; FIRI-SIGG Study Group. Comparing the prognostic accuracy for all-cause mortality of frailty instruments: a multicentre 1-year follow-up in hospitalized older patients. PLoS One. 2012;7(1):e29090. doi: 10.1371/journal.pone.0029090. Epub 2012 Jan 11.</citation>
    <PMID>22247767</PMID>
  </reference>
  <reference>
    <citation>Volpato S, Bazzano S, Fontana A, Ferrucci L, Pilotto A; MPI-TriVeneto Study Group. Multidimensional Prognostic Index predicts mortality and length of stay during hospitalization in the older patients: a multicenter prospective study. J Gerontol A Biol Sci Med Sci. 2015 Mar;70(3):325-31. doi: 10.1093/gerona/glu167. Epub 2014 Sep 9.</citation>
    <PMID>25209253</PMID>
  </reference>
  <reference>
    <citation>Pilotto A, Panza F, Ferrucci L. A multidimensional prognostic index in common conditions leading to death in older patients. Arch Intern Med. 2012 Apr 9;172(7):594; discussion 594-5. doi: 10.1001/archinternmed.2011.1891.</citation>
    <PMID>22493470</PMID>
  </reference>
  <reference>
    <citation>Angleman SB, Santoni G, Pilotto A, Fratiglioni L, Welmer AK; MPI_AGE Project Investigators. Multidimensional Prognostic Index in Association with Future Mortality and Number of Hospital Days in a Population-Based Sample of Older Adults: Results of the EU Funded MPI_AGE Project. PLoS One. 2015 Jul 29;10(7):e0133789. doi: 10.1371/journal.pone.0133789. eCollection 2015.</citation>
    <PMID>26222546</PMID>
  </reference>
  <reference>
    <citation>Cerreta F, Eichler HG, Rasi G. Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy. N Engl J Med. 2012 Nov 22;367(21):1972-4. doi: 10.1056/NEJMp1209034.</citation>
    <PMID>23171092</PMID>
  </reference>
  <reference>
    <citation>Granziera S, Cohen AT, Nante G, Manzato E, Sergi G. Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm. J Am Med Dir Assoc. 2015 May 1;16(5):358-64. doi: 10.1016/j.jamda.2014.12.008. Epub 2015 Feb 11. Review.</citation>
    <PMID>25680239</PMID>
  </reference>
  <reference>
    <citation>Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124.</citation>
    <PMID>21282258</PMID>
  </reference>
  <reference>
    <citation>Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134. Epub 2010 Mar 18.</citation>
    <PMID>20299623</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2016</study_first_submitted>
  <study_first_submitted_qc>November 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Ospedali Galliera</investigator_affiliation>
    <investigator_full_name>Alberto Pilotto</investigator_full_name>
    <investigator_title>Director of Department Geriatric Care, OrthoGeriatrics and Rehabilitation</investigator_title>
  </responsible_party>
  <keyword>Anticoagulant Treatments</keyword>
  <keyword>Multidimensional Prognostic Index (MPI)</keyword>
  <keyword>Comprehensive Geriatric Assessment (CGA)</keyword>
  <keyword>Frailty</keyword>
  <keyword>Elderly</keyword>
  <keyword>Atrial Fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

